alpha 1A adrenoceptor Inhibitors
2 drugsAbout alpha 1A adrenoceptor
The alpha 1A adrenoceptor (α1A-adrenoceptor) is a G protein-coupled receptor activated by catecholamines like norepinephrine and epinephrine. These receptors mediate the effects of the sympathetic nervous system, influencing various physiological processes.
While the α1A-adrenoceptor's involvement in physiological processes makes it a relevant drug target, there is currently no genetic evidence directly linking it to specific diseases.
Two approved drugs, RHOFADE and CARDURA XL, target the α1A-adrenoceptor, both are small molecules. These drugs, developed by MAYNE PHARMA and Viatris, are used in therapeutic areas beyond major indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Perioperative Respiratory Adverse Events with only 1 trials.
Top alpha 1A adrenoceptor Drugs
Two companies, MAYNE PHARMA and Viatris, have approved drugs targeting this receptor.
Low market concentration suggests relatively low barriers to entry for new competitors.
alpha 1A adrenoceptor Drug Modality Landscape
Modalities
Routes of Administration
alpha 1A adrenoceptor is amenable to small molecule drugs, with oral options available for convenient dosing.
The absence of biologics represents a whitespace opportunity for novel therapeutic modalities.
alpha 1A adrenoceptor Clinical Trials 29 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 10 | 0 | 0 | 100% |
| Phase 2 | 8 | 5 | 1 | 1 | 83% |
| Phase 3 | 4 | 3 | 0 | 1 | 100% |
| Phase 4 | 7 | 5 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
alpha 1A adrenoceptor Drug Approval Timeline (2005 - 2017)
The first drug was approved in 2005, and the most recent in 2017, spanning 13 years.
The approval timeline indicates a potentially unsaturated market with room for further innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 29 clinical trials targeting alpha 1A adrenoceptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities